Biogen Inc.

Eisai on Wednesday said an injectable version of the Alzheimer's drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient option for administering the antibody treatment. …

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.…

Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45…

SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia   Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth, adding a highly…

A Biogen facility in Cambridge, Massachusetts.Brian Snyder | ReutersBiogen on Tuesday said it expects to cut approximately 1,000 jobs, or about 11% of its workforce, to save costs as the biotech company prepares to launch its newly approved…

Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer’s disease New data on subcutaneous formulation shows promising PK /PD data modeling on efficacy…

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.Cristina Arias | Cover | Getty ImagesEli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer's…

The Alzheimer's drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | via ReutersMedicare has agreed to pay for the Alzheimer's treatment Leqembi, a major turning point for patients who are…

Jay Reinstein, who suffers from Alzheimer's, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson Chávez | The Washington Post | Getty ImagesSales of…

The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease The Centers for Medicare & Medicaid Services (CMS) announced broader…